18p-FDG PET is superior to67Ga SPECT in the staging of non-Hodgkin’s lymphoma
- 47 Downloads
Our study aims to compare diagnostic accuracy between18F-FDG PET and67Ga SPECT in the staging of non-Hodgkin’s lymphoma.
Twenty-eight patients with non-Hodgkin’s lymphoma, underwent18F-FDG PET,67Ga SPECT and CT for the pretreatment staging of malignant lymphoma between August 1999 and March 2002.18F-FDG PET imaging was obtained 60 minutes after the intravenous administration of 185 MBq of18F-FDG.67Ga SPECT imaging was obtained 2 days after the intravenous administration of 148 MBq of67Ga.18F-FDG PET and 67Ga SPECT were performed within one month. Both imagings were performed on the area from the neck to the pelvis. The18F-FDG PET and67Ga SPECT findings were compared with the CT findings and the clinical course.
Sixty-six nodal lesions were clinically confirmed. Of these, 32 were identified by both18F-FDG PET and67Ga SPECT. The remaining 34 lesions were identified only by18F-FDG PET. The mean (± SD) sizes of the nodes were 34.7 ± 32.4 mm for18F-FDG-positive and67Ga-positive lesions and 15.7 ± 8.3 mm for18F-FDG-positive and67Ga-negative lesions (p >; 0.001). Of the 23 extranodal lesions, 12 were identified by both18F-FDG PET and67Ga SPECT, whereas 6 lesions were identified by only18F-FDG PET. Five lesions were not identified by either technique. No18F-FDG-negative but67Ga-positive nodal or extranodal lesions were observed. The difference in findings between the two studies is related to the difference in the size but not in the histology or site of the lesions.
18F-FDG PET detected significantly more lesions particularly small lesions than67Ga SPECT. Thus,18F-FDG PET is considered to be superior to67Ga SPECT in the staging of non-Hodgkin’s lymphoma.
Key words18F-FDG 67Ga citrate emission computed tomography non-Hodgkin’s lymphoma
- 9.Valk PE, Pounds TR, Wolkow HB, et al. PET-FDG wholebody imaging in staging Hodgkin’s disease: comparison to conventional imaging.J Nucl Med 1995; 36:199P.Google Scholar
- 16.Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.Blood 1999; 94:429–433.PubMedGoogle Scholar